| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total operating expenses | 434,856 | 459,715 | 598,646 | 808,955 |
| Loss from operations | -8,459 | -107,259 | -192,615 | -327,307 |
| Interest expense and financing costs (including related party interest of 35,455 in the three months ended in march 31, 2025 and 31,063 in march 31, 2024 | - | - | 74,239 | 67,553 |
| Nonoperating income (expense) | - | - | - | -67,553 |
| Interest expense and financing costs (including related party interest of 35,455 in the six months ended in june 30, 2025 and 31,063 in june 30, 2024 | - | 71,086 | - | - |
| Interest expense and financing costs | 72,106 | - | - | - |
| Net loss | -80,565 | -178,345 | -266,854 | -394,860 |
| Foreign currency translation adjustment | 7,222 | -7,197 | -2,059 | -2,561 |
| Other comprehensive loss | -73,343 | -185,542 | -268,913 | -397,421 |
| Loss per share - basic | 0 | 0 | 0 | 0 |
| Loss per share - diluted | 0 | 0 | 0 | 0 |
| Weighted average common shares outstanding - basic | 960,873,144 | 959,205,422 | 956,994,100 | 956,530,100 |
| Weighted average common shares outstanding - diluted | 960,873,144 | 959,205,422 | 956,994,100 | 956,530,100 |
BIOREGENX, INC. (BRGX)
BIOREGENX, INC. (BRGX)